MSLE
Satellos Bioscience, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · CA
$9.32
−3.72%Jul 8, 2026, 13:34 UTC
Satellos Bioscience Inc. reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy.
Source:Jun 29, 2026, 11:53 UTC
The U.S. Food and Drug Administration granted Fast Track designation to Satellos Bioscience's drug candidate SAT-3247 for Duchenne muscular dystrophy.
Source: